Castle Biosciences (CSTL) Operating Leases (2021 - 2025)
Castle Biosciences (CSTL) has disclosed Operating Leases for 5 consecutive years, with $25.2 million as the latest value for Q4 2025.
- Quarterly Operating Leases rose 75.79% to $25.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, up 75.79% year-over-year, with the annual reading at $25.2 million for FY2025, 75.79% up from the prior year.
- Operating Leases hit $25.2 million in Q4 2025 for Castle Biosciences, roughly flat from $25.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $25.4 million in Q2 2025 to a low of $6.5 million in Q2 2022.
- Historically, Operating Leases has averaged $14.2 million across 5 years, with a median of $13.6 million in 2024.
- Biggest five-year swings in Operating Leases: soared 91.77% in 2023 and later increased 1.21% in 2024.
- Year by year, Operating Leases stood at $6.9 million in 2021, then surged by 67.14% to $11.5 million in 2022, then increased by 22.89% to $14.2 million in 2023, then rose by 1.21% to $14.3 million in 2024, then soared by 75.79% to $25.2 million in 2025.
- Business Quant data shows Operating Leases for CSTL at $25.2 million in Q4 2025, $25.3 million in Q3 2025, and $25.4 million in Q2 2025.